Service
Architecture review before implementation
Implementation scope and rollout planning
Clear next-step recommendation
Bridge the gap between complex biological data and actionable clinical insights with purpose-built AI systems.
Modern precision medicine generates vast, siloed datasets—genomic, transcriptomic, proteomic, and clinical. The bottleneck is no longer data generation, but intelligent integration and interpretation. Our Bio-AI systems fuse these modalities to deliver clinically relevant predictions.
We engineer AI that moves from correlation to causation, identifying biomarkers with 40% higher predictive power for treatment response and patient stratification.
WGS, scRNA-seq, and mass spectrometry data with EHRs using graph neural networks and multimodal transformers.Our approach transforms raw data into a strategic asset. Learn how we build compliant, high-impact systems in our guide to Bio-AI Foundation Model Consulting and ensure robustness with Bio-AI Data Pipeline and MLOps Engineering.
Our Bio-AI development services translate complex multi-omic data into clear, competitive advantages. We focus on delivering specific, quantifiable outcomes that accelerate your precision medicine pipeline and de-risk R&D investments.
Identify clinically actionable biomarkers from integrated genomic, transcriptomic, and proteomic data in weeks, not years, using our multimodal fusion pipelines. This accelerates target validation and patient stratification for clinical trials.
Deploy AI models that predict individual patient response to specific therapeutics by analyzing historical clinical records alongside real-time omics data. This enables truly personalized therapeutic strategies and improves trial success probability.
Leverage our optimized Bio-AI MLOps pipelines and efficient model architectures to run high-fidelity simulations and analyses at a fraction of the cloud compute cost of building in-house infrastructure from scratch.
Move beyond siloed data. We engineer unified data lakes and processing pipelines that harmonize WGS, RNA-seq, proteomics, and EHR data, creating a single source of truth for all your AI-driven discovery efforts.
Apply predictive analytics to optimize patient recruitment, site selection, and trial design. Our systems model trial outcomes to identify potential failures early, protecting capital and shortening time to market for new therapies.
Our proven, milestone-driven approach to Bio-AI for Precision Medicine ensures predictable delivery, clear ROI at each phase, and continuous alignment with your clinical and business objectives.
| Phase & Key Deliverables | Timeline | Core Outcomes & Milestones | Investment Range |
|---|---|---|---|
Phase 1: Data Pipeline & Foundational Model Setup | Weeks 1-4 | Integrated multi-omic data lake; Fine-tuned base model (e.g., BioBERT, GNN) on your corpus; Initial biomarker discovery report | $80K - $120K |
Phase 2: Predictive Model Development & Validation | Weeks 5-10 | Validated treatment response predictor (AUC >0.85); Interactive patient stratification dashboard; Technical validation report against historical data | $150K - $220K |
Phase 3: Clinical Integration & Pilot Deployment | Weeks 11-16 | Pilot integration with clinical workflow (e.g., EHR via HL7/FHIR); Live inference API with <100ms latency; Pilot study report with clinician feedback | $100K - $160K |
Phase 4: Full Production & Regulatory Roadmap | Weeks 17-20 | Production-grade MLOps pipeline (99.9% uptime SLA); Comprehensive model card & performance audit; FDA SaMD/IVD readiness assessment report | $70K - $110K |
Ongoing Support & Model Iteration | Post-Launch | Monthly model retraining & performance monitoring; Quarterly feature updates; Dedicated ML engineer support | Starting at $15K/month |
Total Time to Clinical Impact | 16-20 weeks | Deployable, validated AI system for precision treatment planning | $400K - $610K+ |
We deliver production-ready Bio-AI systems for precision medicine through a rigorous, iterative process designed for scientific validation and regulatory readiness. Our methodology ensures models are not just accurate in silico but are actionable in clinical and research settings.
We implement a continuous validation loop using held-out clinical cohorts and synthetic data to stress-test model generalizability. Our reports include SHAP values and attention maps to provide biologically interpretable insights, not just black-box predictions, which is critical for regulatory submission and clinician trust.
We design intuitive interfaces (APIs, dashboards) that integrate seamlessly into existing clinical and research environments like EHR systems and LIMS, ensuring the AI delivers value at the point of decision without disrupting established workflows.
Post-deployment, we implement monitoring for model drift, data quality shifts, and clinical outcome correlation. This proactive system triggers retraining protocols to maintain predictive accuracy as patient populations and treatment paradigms evolve.
Enabling Efficiency, Speed & Accuracy
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Answers to common questions about our Bio-AI development process, timelines, security, and outcomes for precision medicine initiatives.
Our process follows a structured, four-phase methodology designed for technical rigor and regulatory alignment. Phase 1 (2-3 weeks): Discovery & Data Assessment. We conduct a technical deep-dive on your multi-omic data sources, clinical data schemas, and target outcomes. Phase 2 (4-6 weeks): Prototype & Feasibility. We build a proof-of-concept model (e.g., a multimodal classifier for treatment response) on a subset of your data to validate the approach. Phase 3 (8-12 weeks): Full System Development & Validation. We engineer the complete pipeline, including data fusion, model training (using frameworks like PyTorch and libraries for GNNs/transformers), and internal validation against predefined clinical benchmarks. Phase 4 (Ongoing): Deployment & Compliance Support. We assist with integration into your clinical/research environment and prepare documentation for regulatory pathways (FDA, EMA). All phases include weekly technical syncs with your engineering and science leads.
About the author
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
How We Work
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
The first call is a practical review of your use case and the right next step.
